Fig. 4 In vivo siRIPK4 delivered by HNTs inhibits tumor promotion of T24 bladder cancer cells in an in situ model of bladder cancer (n = 12 rats in each group). In vivo siRIPK4 delivered by HNTs inhibits tumor promotion of T24 bladder cancer cells in an in situ model of bladder cancer (n = 12 rats in each group). (A) Representative excised bladders and H&E-stained tissue slices (muscle-invasive bladder cancer: ≥stage pT2) treated with PBS. (B) Representative excised bladders and H&E-stained tissue slices (muscle-invasive bladder cancer: ≥stage pT2) treated with siRIPK4. (C) Representative excised bladders and H&E-stained tissue slices (muscle-invasive bladder cancer: ≥stage pT2) treated with HNTs. (D) Representative excised bladders and H&E-stained tissue slices (noninvasive papillary carcinoma: stage pTa) treated with HNTs/siRIPK4. (Photo credit: Jianye Liu and Ke Cao, The Third Xiangya Hospital of Central South University). Jianye Liu et al. Sci Adv 2019;5:eaaw6499 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).